Inflammatory, Hemostatic, and Other Novel Biomarkers for Diabetic Retinopathy
Open Access
- 23 June 2009
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 32 (9) , 1704-1709
Abstract
OBJECTIVE: There are conflicting data regarding relationships of systemic biomarkers of inflammation, hemostasis, and homocysteine with diabetic retinopathy. We examined these relationships in the Multi-Ethnic Study of Atherosclerosis. RESEARCH DESIGN AND METHODS: A total of 921 participants with diabetes were included. Diabetic retinopathy was graded from retinal photographs. We defined two outcomes: any diabetic retinopathy and vision-threatening diabetic retinopathy (severe nonproliferative diabetic retinopathy or worse). Systemic markers analyzed were C-reactive protein, homocysteine, fibrinogen, plasmin-α2-antiplasmin complex (PAP), interleukin-6, d-dimer, factor VIII, serum creatinine, and urinary albumin-to-creatinine (UAC) ratio. RESULTS: Prevalence of diabetic retinopathy was 33.2% and vision-threatening diabetic retinopathy 7.1%. After adjusting for established risk factors (diabetes duration, A1C, systolic blood pressure, waist-to-hip ratio, and use of diabetes medications), fibrinogen (odds ratio 1.14 [95% CI 1.01–1.32], P = 0.05) and PAP (1.25 [1.05–1.50], P = 0.01) were associated with any diabetic retinopathy, while PAP (1.54 [1.13–2.11], P = 0.007) and homocysteine (1.57 [1.16–2.11], P = 0.003) were associated with vision-threatening diabetic retinopathy. Only PAP remained significant after additional adjustment for serum creatinine and UAC ratio. Area under receiver-operator characteristic curve (AUROC) for diabetic retinopathy was constructed for established and novel risk factors. Established risk factors accounted for a 39.2% increase of the AUROC, whereas novel markers (fibrinogen, PAP, homocysteine, serum creatinine, and UAC ratio) only accounted for an additional 2.2%. CONCLUSIONS: There were few associations of novel markers of inflammation, hemostasis, and homocysteine with diabetic retinopathy after controlling for established risk factors. These data suggest that there is limited clinical use of these biomarkers for prediction of diabetic retinopathy.Keywords
This publication has 24 references indexed in Scilit:
- Homocysteine, S-adenosylmethionine and S-adenosylhomocysteine are associated with retinal microvascular abnormalities: the Hoorn StudyClinical Science, 2008
- Homocysteine and Diabetic RetinopathyDiabetes Care, 2008
- Retinal Vascular Changes in Pre-Diabetes and PrehypertensionDiabetes Care, 2007
- Management of Diabetic RetinopathyJAMA, 2007
- Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross‐sectional nested case–control studyJournal of Internal Medicine, 2005
- Coagulation and Fibrinolysis Parameters in Type 2 Diabetic Patients with and without Diabetic Vascular ComplicationsMedical Principles and Practice, 2004
- A central role for inflammation in the pathogenesis of diabetic retinopathyThe FASEB Journal, 2004
- Multi-Ethnic Study of Atherosclerosis: Objectives and DesignAmerican Journal of Epidemiology, 2002
- Fibrinolytic Activation Markers Predict Myocardial Infarction in the ElderlyArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease.Diabetes Care, 1999